The IRS study is valued at 55 752 Euros. It will be carried out at IMM's research facilities at Karolinska Insittutet in Stockholm under the leadership of KI's Professor Lena Palmberg, a long-term ISAB collaborator.

The study will use XposeALI[®], ISAB's highly innovative in vitro cell culturing tool that combines the aerosol capability from PreciseInhale[®] with cell exposures at an Air Liquid Interface that mimic closely the physiologic processes as they happen in the lungs.

2021 has seen significant events around XposeALI[®]: in October it was chosen to test a Mars dust surrogate for the European Space Agency in another IMM research project. In the same month its US patent was extended. In November the module received its US Registered Trademark, together with ISAB's core aerosol generating system PreciseInhale[®] and in vitro dissolution module DissolvIt[®].

CEO Manoush Masarrat: "Both Chiesi and KI are recognized worldwide as leading bodies in inhalation research. It is a powerful endorsement of our technology that they choose us time and again to achieve their early stage results. We are delighted too to see them recognize the unique capabilities and benefits of XposeALI[®]. We believe it will become a recognized leader within its niche."